|
|
Volumn 10, Issue 21, 2006, Pages
|
|
Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
ALPHA2B INTERFERON;
ANTIVIRUS AGENT;
MACROGOL DERIVATIVE;
PEGINTERFERON ALPHA2B;
RECOMBINANT PROTEIN;
RIBAVIRIN;
ADULT;
ANALYSIS OF VARIANCE;
ARTICLE;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COST BENEFIT ANALYSIS;
COST OF ILLNESS;
DRUG COMBINATION;
DRUG EFFECT;
ECONOMICS;
FEMALE;
GENETICS;
GENOTYPE;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
MALE;
MULTICENTER STUDY;
QUALITY ADJUSTED LIFE YEAR;
QUALITY OF LIFE;
QUESTIONNAIRE;
RANDOMIZED CONTROLLED TRIAL;
TREATMENT OUTCOME;
UNITED KINGDOM;
VIRUS LOAD;
ADULT;
ANALYSIS OF VARIANCE;
ANTIVIRAL AGENTS;
COST OF ILLNESS;
COST-BENEFIT ANALYSIS;
DRUG THERAPY, COMBINATION;
FEMALE;
GENOTYPE;
GREAT BRITAIN;
HEPACIVIRUS;
HEPATITIS C, CHRONIC;
HUMANS;
INTERFERON-ALPHA;
MALE;
POLYETHYLENE GLYCOLS;
QUALITY OF LIFE;
QUALITY-ADJUSTED LIFE YEARS;
QUESTIONNAIRES;
RECOMBINANT PROTEINS;
RIBAVIRIN;
TREATMENT OUTCOME;
VIRAL LOAD;
|
|
EID: 84891685662
PISSN: 13665278
EISSN: None
Source Type: Journal
DOI: 10.3310/hta10210 Document Type: Article |
|
Times cited : (93)
|
|
References (0)
|
